Ocular Therapeutix Inc (OCUL)
NASDAQ:OCUL
Want to see OCUL full AI Analyst Report?
Top Page
Ocular Therapeutix
(NASDAQ:OCUL)
Select Model
Select Model
Rating:50Neutral
Price Target:
$9.50
▼(-3.26% Downside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by very large operating losses and substantial negative operating/free cash flow, despite strong gross margins and a relatively low-leverage balance sheet. Technicals contribute modest support (positive near-term momentum but weak longer-term trend), while valuation is constrained by a negative P/E and no dividend. A positive Phase 3 update provides incremental upside but is secondary to current financial burn.
Positive Factors
High gross margins
Sustained product-level gross margins near 87%–91% indicate strong unit economics for DEXTENZA and similar products. Durable margins mean each incremental sale contributes meaningfully to covering fixed costs and can support scale-up and profitability as revenues grow.
Negative Factors
Very large operating losses
TTM net and EBIT margins deeply negative indicate the business is far from profitability. Persistent large operating losses erode equity, heighten reliance on external funding, and increase execution risk for commercialization and pipeline development over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained product-level gross margins near 87%–91% indicate strong unit economics for DEXTENZA and similar products. Durable margins mean each incremental sale contributes meaningfully to covering fixed costs and can support scale-up and profitability as revenues grow.
Read all positive factors
Ocular Therapeutix (OCUL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.01B
Dividend YieldN/A
Average Volume (3M)3.63M
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth-12.76%
EPS Growth-26.75%
CountryUS
Employees274
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.46
Shares Outstanding218,960,360
10 Day Avg. Volume3,507,434
30 Day Avg. Volume3,625,872
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)3.47
Price to Sales (P/S)43.86
P/FCF Ratio-10.48
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue27.26
Enterprise Value/Gross Profit31.25
Enterprise Value/Ebitda-5.03
Forecast
1Y Price Target
$24.50Price Target Upside149.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.34
Revenue Forecast (FY)$55.68M
Ocular Therapeutix Business Overview & Revenue Model
Company Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company ma...
How the Company Makes Money
Ocular Therapeutix generates revenue primarily from commercialization of its FDA-approved product DEXTENZA, an intracanalicular insert that delivers dexamethasone for post-surgical ocular inflammation and pain (and has also been approved for itchi...
Ocular Therapeutix Earnings Call Summary
Earnings Call Date:Nov 04, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 10, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and financial stability, with strong support from payers and successful trial execution. However, challenges such as market pricing pressure and potential enrollment difficulties in diabetic retinopathy trials were noted.Positive Updates
SOL-R Reaches Target Randomization
SOL-R has reached its target randomization of 555 subjects, marking a significant milestone and reflecting exceptional execution and investigator enthusiasm.
Negative Updates
Pricing Pressure in Wet AMD
The wet AMD market is defined by step therapy restrictions and rapid discounting, leading to a pricing race to the bottom.
Read all updates
Q3-2025 Updates
Positive
Negative
SOL-R Reaches Target Randomization
SOL-R has reached its target randomization of 555 subjects, marking a significant milestone and reflecting exceptional execution and investigator enthusiasm.
Read all positive updates
Company Guidance
During the Ocular Therapeutix Third Quarter 2025 Earnings Conference Call, the company provided extensive guidance on its ongoing and future clinical trials, emphasizing the transformative potential of their drug AXPAXLI (OTX-TKI) for wet age-related macular degeneration (AMD) and diabetic retinopathy. Key metrics included the successful randomization of 555 subjects in the SOL-R trial, anticipated top line data from the SOL-1 trial in Q1 2026, and the planned HELIOS program, which aims to secure a broad label for diabetic retinopathy and diabetic macular edema (DME). The company highlighted its strategic triad of potential superiority labeling, market expansion, and immediate adaptability, supported by a robust cash position of $345 million at the end of Q3 2025, supplemented by $445 million from a recent financing. These initiatives aim to redefine the retina market by addressing the $15 billion global anti-VEGF sector's unmet needs and improving patient adherence and treatment outcomes.Ocular Therapeutix Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
63
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.04M | 51.82M | 63.72M | 58.44M | 51.49M | 43.52M |
| Gross Profit | 45.40M | 45.25M | 58.10M | 53.16M | 46.95M | 39.12M |
| EBITDA | -281.75M | -249.78M | -176.14M | -66.42M | -61.91M | 2.54M |
| Net Income | -290.50M | -265.94M | -193.51M | -80.74M | -71.04M | -6.55M |
Balance Sheet | ||||||
| Total Assets | 732.53M | 808.06M | 457.94M | 252.06M | 149.29M | 204.89M |
| Cash, Cash Equivalents and Short-Term Investments | 666.70M | 737.06M | 392.10M | 195.81M | 102.30M | 164.16M |
| Total Debt | 79.46M | 79.78M | 75.78M | 83.39M | 64.28M | 58.98M |
| Total Liabilities | 150.96M | 153.75M | 142.59M | 160.93M | 113.91M | 116.89M |
| Stockholders Equity | 581.57M | 654.31M | 315.34M | 91.13M | 35.38M | 88.00M |
Cash Flow | ||||||
| Free Cash Flow | -240.94M | -216.89M | -135.97M | -76.32M | -63.32M | -66.74M |
| Operating Cash Flow | -226.21M | -204.88M | -134.68M | -70.23M | -59.60M | -65.55M |
| Investing Cash Flow | -14.61M | -11.88M | -1.29M | -6.09M | -3.71M | -1.19M |
| Financing Cash Flow | 557.83M | 561.72M | 332.11M | 169.83M | 1.45M | 2.85M |
Ocular Therapeutix Technical Analysis
Positive
9.82
Price Trends
8.82
Positive
10.39
Negative
11.10
Negative
Market Momentum
0.07
Negative
61.68
Neutral
74.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OCUL, the sentiment is Positive. The current price of 9.82 is above the 20-day moving average (MA) of 8.46, above the 50-day MA of 8.82, and below the 200-day MA of 11.10, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 61.68 is Neutral, neither overbought nor oversold. The STOCH value of 74.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OCUL.
Ocular Therapeutix Risk Analysis
Ocular Therapeutix disclosed 53 risk factors in its most recent earnings report. Ocular Therapeutix reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ocular Therapeutix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $5.72B | -52.96 | -22.95% | ― | ― | -94.37% | |
62 Neutral | $2.87B | -6.52 | -5.89% | ― | 157.97% | 86.11% | |
58 Neutral | $2.69B | -108.13 | -14.19% | ― | 128.99% | 58.46% | |
52 Neutral | $737.28M | -3.29 | -100.29% | ― | 1.92% | -1130.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $2.01B | -5.36 | -64.55% | ― | -12.76% | -26.75% |
* Healthcare Sector Average
OCUL
Ocular Therapeutix
9.16
1.65
21.97%
BEAM
Beam Therapeutics
27.93
10.27
58.15%
TARS
Tarsus Pharmaceuticals
62.48
17.47
38.81%
SPRY
ARS Pharmaceuticals
7.43
-6.84
-47.93%
BLTE
Belite Bio, Inc. ADR
143.00
78.00
120.00%
Ocular Therapeutix Corporate Events
Business Operations and StrategyProduct-Related Announcements
Ocular Therapeutix Highlights Phase 3 AXPAXLI Trial Progress
Positive
Feb 27, 2026
On February 27, 2026, Ocular Therapeutix announced that it would post investor presentation slides on its corporate website at 4:15 p.m. Eastern Time. The materials detail results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI (OTX-T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.